Frank Torti

Frank Torti, M.D. is Chairperson of Immunovant’s board of directors. Since January 2020, Dr. Torti served as the Vant Chair of Roivant Sciences, Inc. (RSI), where he previously worked as Vant Investment Chair. Prior to joining RSI, Dr. Torti served as a Partner of New Enterprise Associates (NEA), specializing in investments in healthcare. Before NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the board of directors of Arbutus Biopharma Corp., Axovant Gene Therapies Ltd. and several private biopharmaceutical companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.